PHVS Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Pharvaris N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.54 |
| 52 Week High | US$33.00 |
| 52 Week Low | US$15.37 |
| Beta | -3.17 |
| 1 Month Change | -6.27% |
| 3 Month Change | 1.87% |
| 1 Year Change | -26.78% |
| 3 Year Change | 11.02% |
| 5 Year Change | n/a |
| Change since IPO | -36.07% |
Recent News & Updates
Pharvaris: Despite 30% Decline, Still Fair At Best
Dec 29Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation
Dec 02
Recent updates
Pharvaris: Despite 30% Decline, Still Fair At Best
Dec 29Here's Why We're Not Too Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Situation
Dec 02We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Aug 16Pharvaris: Digging Deep For Sufficient Market Size
Jan 17We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Oct 09Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
May 13Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth
Jan 11We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth
Sep 26Pharvaris GAAP EPS of -€0.38
Sep 12Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate
Aug 22We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Jun 08Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans
Dec 21We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate
Aug 25Pharvaris reports Q1 results
May 26Shareholder Returns
| PHVS | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.9% | -1.7% | -2.6% |
| 1Y | -26.8% | 3.2% | 24.5% |
Return vs Industry: PHVS underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.
Return vs Market: PHVS underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| PHVS volatility | |
|---|---|
| PHVS Average Weekly Movement | 9.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHVS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PHVS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 92 | Berndt Axel Modig | pharvaris.com |
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Pharvaris N.V. Fundamentals Summary
| PHVS fundamental statistics | |
|---|---|
| Market cap | US$1.04b |
| Earnings (TTM) | -US$135.60m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs PHVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHVS income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €132.21m |
| Earnings | -€132.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHVS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 22:41 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pharvaris N.V. is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Alexandru Cogut | Bryan Garnier & Co |
| Jonathan Wolleben | JMP Securities |